Glycolic Acid for Hyperpigmentation: Free-Acid Fraction, Direct Melanogenesis Inhibition, and PIH-Safe Formulation Science (2026 Formula Science Review)

Most ingredient decks file glycolic acid under a single word: exfoliant. That classification quietly costs efficacy. Used properly, glycolic acid for hyperpigmentation is not a surface abrasive but a multi-target agent — it clears melanin-loaded corneocytes, directly suppresses melanin synthesis inside melanocytes, and lowers stratum corneum resistance for every other brightening active in the formula.

The catch is that the number on the carton — 5%, 8%, 10% — is not the dose the skin receives. That is set by the free-acid fraction, a function of pH rather than label claim. This review covers mechanism, clinical evidence, the free-acid mathematics, and the post-inflammatory hyperpigmentation risk governing use in melanin-rich skin.

Molecular Profile: Why Size Matters

INCI: Glycolic Acid. CAS 79-14-1. C₂H₄O₃, MW 76.05 g/mol, pKa 3.83. It is the smallest alpha-hydroxy acid in cosmetic use, giving the highest molar flux across the stratum corneum of any AHA at equal weight percentage. At 5% w/w it delivers roughly 1.7 times the molar dose of lactic acid and 2.0 times that of mandelic acid (MW 152.15).

Three Mechanisms in Pigmentation Control

1. Corneodesmolysis and Pigment Clearance

Glycolic acid weakens ionic bonding at the corneodesmosome, accelerating desquamation. Ditre et al. (1996) applied a 25% AHA lotion to forearm skin for six months and documented approximately 25% increase in skin thickness with epidermal and dermal remodelling on histology. For pigment the effect is mechanical: melanin-laden corneocytes turn over faster and epidermal pigment fades.

2. Direct Inhibition of Melanogenesis

The underrated pathway. Usuki et al. (2003) showed that glycolic acid and lactic acid directly inhibited tyrosinase activity and reduced melanin content in cultured melanoma cells at sub-cytotoxic concentrations. That reframes the ingredient entirely: it exerts measurable control at the synthesis step, so it belongs in the active column rather than the adjunct column.

3. Penetration Enhancement for Co-Actives

By loosening the corneocyte scaffold, glycolic acid raises the delivered flux of co-formulated hydrophilic actives — tranexamic acid, niacinamide, arbutin. This is its highest-leverage role: a modest glycolic dose paired with a strong tyrosinase inhibitor routinely outperforms a large dose used alone. Bernstein et al. (2001) add a dermal dividend, reporting increased type I collagen mRNA and hyaluronic acid content after treatment.

The Free-Acid Fraction: The Only Specification That Matters

Only the protonated, uncharged form partitions efficiently into the lipid-rich stratum corneum; the glycolate anion largely stays put. Henderson-Hasselbalch fixes the split: free acid (%) = 100 / (1 + 10^{(pH − 3.83)}).

One conclusion is unavoidable: a 10% serum buffered to pH 5.0 delivers less bioavailable acid than a 1% serum at pH 3.0. A percentage disclosed without pH is marketing, not a specification. Specify internally by bioavailable acid value (BAV = total acid % × free-acid fraction) and hold BAV as the batch release parameter.

Partial neutralisation is the correct tool: neutralising with sodium hydroxide or arginine generates glycolate in situ, and that conjugate-base pair buffers maximally near pH 3.8, resisting drift in the pack and skin-surface neutralisation on application.

Clinical Evidence

1. Sarkar et al. (2002) — Forty predominantly Fitzpatrick IV–V melasma patients; serial glycolic acid peels plus a topical regimen beat the topical regimen alone on modified MASI at 21 weeks. The most directly relevant dataset for Southeast Asian design.
2. Lim & Tham (1997) — Split-face glycolic acid peels in Asian women with melasma over 26 weeks; the peel-treated side showed additional improvement over bilateral topical therapy alone.
3. Erbil et al. (2007) — Serial peels plus topical regimen in recalcitrant melasma produced significant MASI reduction with acceptable tolerability.
4. Kornhauser et al. (2010) — AHAs measurably increase UV sensitivity during and shortly after use, making photoprotection a formulation requirement rather than a usage suggestion.

The PIH Paradox in Melanin-Rich Skin

This is where programmes fail in tropical markets. An over-aggressive acid dose triggers keratinocyte release of interleukin-1 alpha, prostaglandin E2 and endothelin-1 — precisely the paracrine cascade that upregulates melanogenesis in Fitzpatrick IV–VI skin. Overshoot, and the product generates the pigment it was meant to remove.

• Cap leave-on BAV at 2–4% for daily tropical use, where occlusion and sweat raise effective exposure.
• Do not go below pH 3.5 in daily leave-on products for Fitzpatrick IV–VI; reserve lower pH for rinse-off or professional protocols.
• Choose frequency over intensity. Nightly low-BAV exposure beats weekly high-BAV shocks with far less irritation.
• Always co-formulate an anti-inflammatory brake — niacinamide, panthenol, bisabolol or Centella asiatica — to blunt the IL-1 alpha limb.

Formulation Guide: Nightly Brightening Serum

Never use carbomer. Carbomer requires neutralisation above pH 5 to build viscosity; at pH 3.9 the coil collapses and the product thins on standing. Use hydroxyethylcellulose, xanthan gum, or a polyacrylate rated for acidic systems.

Chelation is non-negotiable. Trace iron and copper in technical-grade acid catalyse discolouration and destabilise tranexamic acid. Specify 0.1% disodium EDTA and set a heavy-metal limit on the raw material specification.

The niacinamide compromise. Niacinamide slowly hydrolyses below pH 4.0 to nicotinic acid, which causes transient flushing. Either quantify it by HPLC after 12 weeks at 40 °C, or move niacinamide to a morning product and substitute 2% alpha-arbutin here.

Regulatory. The Cosmetic Ingredient Review panel concluded AHAs are safe for consumers up to 10% total acid at pH 3.5 or above with sun protection directions, and 30% at pH 3.0 professionally; US FDA guidance recommends a sunburn-alert statement. EU limits under Regulation (EC) No 1223/2009 are tighter following SCCS review — verify the current Annex III entry and its ASEAN Cosmetic Directive equivalent at notification.

Summary

Glycolic acid for hyperpigmentation earns its place on three counts: it clears pigmented corneocytes, it directly inhibits tyrosinase, and it raises the delivered dose of every hydrophilic brightening active beside it. What it will not tolerate is casual specification — the free-acid fraction, not the label percentage, decides both efficacy and irritation, and in Fitzpatrick IV–VI skin a dose that clears pigment too fast regenerates it through inflammatory melanogenesis.

Specify by bioavailable acid value, hold daily leave-on exposure in the 2–4% BAV band, buffer near pH 3.9 with a partially neutralised acid-glycolate pair, and always pair the acid with an anti-inflammatory brake.

References

1. Usuki A, Ohashi A, Sato H, et al. The inhibitory effect of glycolic acid and lactic acid on melanin synthesis in melanoma cells. Exp Dermatol. 2003;12(Suppl 2):43-50.
2. Sarkar R, Kaur C, Bhalla M, Kanwar AJ. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients. Dermatol Surg. 2002;28(9):828-832.
3. Lim JT, Tham SN. Glycolic acid peels in the treatment of melasma among Asian women. Dermatol Surg. 1997;23(3):177-179.
4. Erbil H, Sezer E, Tastan B, et al. Efficacy and safety of serial glycolic acid peels and a topical regimen in recalcitrant melasma. J Dermatol. 2007;34(1):25-30.
5. Ditre CM, Griffin TD, Murphy GF, et al. Effects of alpha-hydroxy acids on photoaged skin. J Am Acad Dermatol. 1996;34(2 Pt 1):187-195.
6. Bernstein EF, Lee J, Brown DB, et al. Glycolic acid treatment increases type I collagen mRNA and hyaluronic acid content of human skin. Dermatol Surg. 2001;27(5):429-433.
7. Kornhauser A, Coelho SG, Hearing VJ. Applications of hydroxy acids: classification, mechanisms, and photoactivity. Clin Cosmet Investig Dermatol. 2010;3:135-142.
8. Cosmetic Ingredient Review Expert Panel. Final report on the safety assessment of glycolic acid and related alpha-hydroxy acids. Int J Toxicol. 1998;17(Suppl 1):1-241.